Study: Similar safety, efficacy with dabigatran versus warfarin in diabetic patients with Afib


Patients with nonvalvular atrial fibrillation (NVAF) who also have diabetes experienced similar safety and efficacy with dabigatran etexilate mesylate (Pradaxa) 150 mg or dabigatran 110 mg relative to warfarin, in comparison to patients without diabetes who have NVAF, according to data presented at American Heart Association's Scientific Sessions 2012.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.